BRAF wt Allele Completed Phase 2 Trials for Ceritinib (DB09063)

IndicationStatusPhase
DBCOND0105238 (BRAF wt Allele)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02587650Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV MelanomaTreatment